NovaBay Pharmaceuticals (NBY) 10-K 23 Mar 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 22, 2017	Jun. 30, 2016
Document Information [Line Items]
Entity Registrant Name	NOVABAY PHARMACEUTICALS, INC.
Entity Central Index Key	1,389,545
Trading Symbol	nby
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		15,288,175
Entity Public Float			$ 7,530,005
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 9,512,000	$ 2,385,000
Accounts receivable, net of allowance for doubtful accounts ($10 and $40 at December 31 2016, and December 31, 2015, respectively)	2,120,000	536,000
Inventory, net of allowance for excess and obsolete inventory ($196 and $45 at December 31, 2016 and 2015, respectively)	873,000	1,345,000
Prepaid expenses and other current assets	1,966,000	261,000
Total current assets	14,471,000	4,527,000
Property and equipment, net	371,000	395,000
Other assets	539,000	155,000
TOTAL ASSETS	15,381,000	5,077,000
Current liabilities:
Accounts payable	455,000	2,483,000
Accrued liabilities	1,801,000	1,980,000
Deferred revenue	2,067,000	170,000
Total current liabilities	4,323,000	4,633,000
Deferred revenue - non-current	1,986,000	2,248,000
Deferred rent	327,000	189,000
Notes payable, related party		1,655,000
July 2011 Warrants, Warrant Liability	1,446,000	1,450,000
Other liabilities	198,000
Total liabilities	8,280,000	10,175,000
Commitments and contingencies (Note 9)
Stockholders' equity (deficit):
Preferred stock: 5,000 shares authorized; none outstanding at December 31, 2016 and 2015
Common stock, $0.01 par value; 240,000 shares authorized 15,269 and 3,486 shares issued and outstanding at December 31, 2016 and 2015, respectively	153,000	35,000
Additional paid-in capital	110,619,000	85,387,000
Accumulated other comprehensive loss
Accumulated deficit	(103,671,000)	(90,520,000)
Total stockholders' equity (deficit)	7,101,000	(5,098,000)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 15,381,000	$ 5,077,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accounts receivable, allowance for doubtful accounts	$ 10	$ 40
Inventory, allowance for obsolete inventory accounts and lower cost market	$ 196	$ 45
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	240,000,000	240,000,000
Common stock, shares issued (in shares)	15,269,000	3,486,000
Common stock, shares outstanding (in shares)	15,269,000	3,486,000

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Sales:
Product Revenue, net	$ 11,617	$ 4,146	$ 684
Other Revenue, net	280	235	370
Total Sales, net	11,897	4,381	1,054
Product Cost of Goods Sold	2,464	1,261	486
Gross Profit	9,433	3,120	568
Research and development	1,371	5,728	9,483
Sales and marketing	11,809	10,523	1,754
General and administrative	7,235	8,006	6,235
Total Operating Expenses	20,415	24,257	17,472
Operating Loss	(10,982)	(21,137)	(16,904)
Non-cash gain (loss) on changes in fair value of warrant liability	(2,099)	2,149	1,664
Other income (expense), net	(68)	17	48
Loss before provision for income taxes	(13,149)	(18,971)	(15,192)
Provision for income tax	(2)	(2)	(2)
Net loss	(13,151)	(18,973)	(15,194)
Change in Unrealized gains on available for sale securities			15
Comprehensive loss	$ (13,151)	$ (18,973)	$ (15,179)
Loss per share (basic and diluted) (in dollars per share)	$ (1.40)	$ (6.82)	$ (7.65)
Basic and Diluted Shares used in loss per share calculation (in shares)	9,408	2,784	1,985

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Shelf Offering [Member]Common Stock [Member]	Shelf Offering [Member]Additional Paid-in Capital [Member]	Shelf Offering [Member]	Pioneer Pharma Co. [Member]Additional Paid-in Capital [Member]	Pioneer Pharma Co. [Member]	Employee [Member]Common Stock [Member]	Employee [Member]Additional Paid-in Capital [Member]	Employee [Member]	Nonemployees [Member]Common Stock [Member]	Nonemployees [Member]Additional Paid-in Capital [Member]	Nonemployees [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2013												1,785,000
Balance at Dec. 31, 2013												$ 18	$ 64,866	$ (15)	$ (56,353)	$ 8,516
Net loss															(15,194)	(15,194)
Change in unrealized gains (losses) on investments														$ 15		$ 15
Issuance of common stock (in shares)	275,000
Issuance of common stock	$ 3	$ 7,122	$ 7,125	$ 205	$ 205
Issuance of stock for option exercises (in shares)												2,000				2,000
Issuance of stock for option exercises													34			$ 34
Issuance of stock to consultants for services (in shares)												2,000
Issuance of stock to consultants for services													28			28
Employee bonus paid in common stock (in shares)												1,000
Employee bonus paid in common stock													77			77
Stock-based compensation expense related to employee and director stock options													853			853
Stock-based compensation expense related to non-employee stock options													189			189
Vesting of employee restricted stock awards (in shares)												1,000
Balance (in shares) at Dec. 31, 2014												2,066,000
Balance at Dec. 31, 2014												$ 21	73,374		(71,547)	1,848
Net loss															(18,973)	(18,973)
Issuance of common stock (in shares)	85,000											4,000
Issuance of common stock	$ 1	1,176	1,177
Issuance of stock to consultants for services													63			63
Employee bonus paid in common stock (in shares)												3,000
Employee bonus paid in common stock													62			62
Stock-based compensation expense related to employee and director stock options													1,194			1,194
Stock-based compensation expense related to non-employee stock options													188			188
Balance (in shares) at Dec. 31, 2015												3,486,000
Balance at Dec. 31, 2015												$ 35	85,387		(90,520)	(5,098)
Issuance of stock and warrants, net of offering costs (in shares)												1,328,000
Issuance of stock and warrants, net offering costs												$ 13	11,505			11,518
Equity transferred to warrant liability													(2,175)			(2,175)
Net loss															(13,151)	$ (13,151)
Issuance of common stock (in shares)	7,692,000											2,000
Issuance of common stock	$ 77	$ 13,571	$ 13,648
Issuance of stock for option exercises (in shares)																0
Issuance of stock to consultants for services													8			$ 8
Stock-based compensation expense related to employee and director stock options													1,316			1,316
Stock-based compensation expense related to non-employee stock options													269			269
Balance (in shares) at Dec. 31, 2016												15,269,000
Balance at Dec. 31, 2016												$ 153	110,619		$ (103,671)	7,101
Issuance of stock and warrants, net of offering costs (in shares)	3,977,000
Issuance of stock and warrants, net offering costs												$ 40	7,389			7,429
Fair market value of warrants transferred to equity upon exercise													2,103			2,103
Warrant modification													$ 270			$ 270
Vesting of restricted stock awards (in shares)						73,000			41,000
Vesting of restricted stock awards						$ 1	$ 173	$ 174		$ 133	$ 133
Shares retired as a result of the 1 for 25 reverse stock split (in shares)												(2,000)

Consolidated Statements of Sto6

Consolidated Statements of Stockholders' Equity (Deficit) (Parentheticals)	Dec. 11, 2015	Dec. 31, 2016
Reverse Stock Split [Member]
Reverse Stock Split	25	25

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss	$ (13,151)	$ (18,973)	$ (15,194)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	114	164	232
Net realized loss on sales of short-term investments			40
Gain on sale and disposal of property and equipment	(219)	(1)	(54)
Issuance of RSUs to employees	173
Issuance of RSUs to non-employees	133
Fair Value Adjustment of Warrants	270
Note receivable impairment	91
Non-cash (gain) loss on change in fair value of warrant liability	2,099	(2,149)	(1,664)
Property and equipment impairment	70
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable	(1,585)	(299)	555
Increase (decrease) in inventory	472	(751)	(451)
(Increase) decrease in prepaid expenses and other assets	(1,470)	402	102
Increase in other assets long-term	(474)
Increase (decrease) in accounts payable and accrued liabilities	(2,162)	1,655	(252)
Increase in deferred rent	327	17	36
Increase in accrued taxes	87
Increase (decrease) in deferred revenue	1,447	(6)	553
Increase in other liabilities long-term	198
Net cash used in operating activities	(12,135)	(18,559)	(15,055)
Cash flows from investing activities:
Purchases of property and equipment	(160)	(123)	(68)
Proceeds from disposal of property and equipment		37	128
Purchases of short-term investments			(4,012)
Proceeds from maturities and sales of short-term investments			6,550
Net cash provided (used) by investing activities	(160)	(86)	2,598
Cash flows from financing activities:
Proceeds from common stock issuances, net	13,648	11,519	227
Proceeds from exercise of options and warrants	7,429	1,250	34
Proceeds from borrowings	1,365	1,655
Repayment of borrowings	(3,020)
Proceeds from shelf offering, net		1,177	7,125
Net cash provided by financing activities	19,422	15,601	7,386
Net increase (decrease) in cash and cash equivalents	7,127	(3,044)	(5,071)
Cash and cash equivalents, beginning of period	2,385	5,429	10,500
Cash and cash equivalents, end of period	9,512	2,385	5,429
Supplemental disclosure of non-cash information:
Stock issued to consultants for services	8	63	7
Property and equipment purchases, included in accounts payable and accrued liabilities	60
Cash paid for interest	51
Options exercised		(4)
Warrant liability transferred to (from) equity	2,103	(2,175)
Exchange of equipment for services	279
Employees and Directors [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense for options and stock issued	1,316	1,194	853
Nonemployees [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense for options and stock issued	129	188	189
Bonus Paid in Stock [Member]
Supplemental disclosure of non-cash information:
Other significant noncash transaction		62	54
Severance Paid in Restricted Stock Units to Non-employees [Member]
Supplemental disclosure of non-cash information:
Other significant noncash transaction	$ 140

Note 1 - Organization

Note 1 - Organization	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1. NovaBay Pharmaceuticals, Inc. (the “Company”) is a pharmaceutical company focused on commercializing prescription Avenova® daily lid and lash hygiene in the domestic eye care market. The Company was incorporated under the laws of the State of California on January 19, 2000, July 1, 2002, February 2007, August 2007, two July 2012, may June 2010, four single four Effective December 11, 2015, 1 25 11). Liquidity With the funds available at December 31, 2016, 2018. 2017 2017 may (1) (2) (3) one (4) may 1 3 may

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and are expressed in U.S. dollars. Reclassifications Prior period amounts in the accompanying consolidated balance sheets have been reclassified to conform to current period presentation. The reclassifications did not change total assets, total liabilities, or total stockholders’ equity. Additionally, prior period amounts in the accompanying consolidated statement of operations and comprehensive loss and have been reclassified to conform to current period presentation. The reclassifications did not change the net loss or loss per share Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, DermaBay, which was dissolved by the Company in April 2016. Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization period for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates. Cash and Cash Equivalents and Short-Term Investments The Company considers all highly-liquid instruments with a stated maturity of three December 31, 2016, December 31, 2015, three The Company classifies all highly-liquid investments with a stated maturity of greater than three twelve December 31, 2016 December 31, 2015, Concentrations of Credit Risk, Major Partners and Customers, and Suppliers Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits of cash and cash equivalents with three Deposits in these banks may During the years ended December 31, 2016 2015 three December 31, 2014 one As of December 31, 2016, December 31, 2015 December 31, 2014 10% Year Ended December 31, Major distribution or collaboration partner 2016 2015 2014 Distributer A 20 % * * Distributer B 22 % * * Distributer C 16 % * * Collaborator D * * 15 % *Not greater than 10% As of December 31, 2016, December 31, 2015 10% Year Ended December 31, Major distribution or collaboration partner 2016 2015 Distributer A 22 % 36 % Distributer B 24 % 11 % Distributer C 31 % * *Not greater than 10% The Company relies on two third third may Fair Value of Financial Assets and Liabilities Financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Our warrant liability is carried at fair value. The Company measures the fair value of financial assets and liabilities based on U.S. GAAP guidance, which defines fair value, establishes a framework for measuring fair value, and requires disclosures about fair value measurements. Under U.S. GAAP, fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is also established, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three may Level 1 Level 2 Level 3 Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it unlikely a specific invoice will be collected. Management identifies amounts due that are in dispute and it believes are unlikely to be collected at the end of 2016. December 31, 2016 December 31, 2015, $10 $40 120 Inventory Inventory is comprised of (1) (2) (3) December 31, 2016 2015, $196 $45 Inventory is stated at the lower of cost or market value determined by the first first Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three seven seven The costs of normal maintenance, repairs, and minor replacements are charged to operations when incurred. In September 2016, $66 third 2016, December 31, 2016. Impairment of Long-Lived Assets The Company accounts for long-lived assets in accordance with U.S. GAAP, which requires that companies consider whether events or changes in facts and circumstances, both internally and externally, may first 2016, $91 first 2016, December 31, 2016. Comprehensive Income (Loss) ASC 220, Comprehensive Income, Revenue Recognition The Company sells products through a limited number of distributors and via its webstore. The Company generally records product sales upon shipment to the final customer for its webstore sales and upon shipment from its distributor to the final customers for its major distribution partners. The Company recognizes product revenue when: (i) persuasive evidence that a sale arrangement exists; (ii) delivery has occurred and title has passed; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. Revenue from sales transactions where the customer has the right to return the product is recognized at the time of sale only if: (i) the Company’s price to the customer is substantially fixed or determinable at the date of sale; (ii) the customer has paid the Company, or the customer is obligated to pay the Company and the obligation is not contingent on resale of the product; (iii) the customer's obligation to the Company would not be changed in the event of theft or physical destruction or damage of the product; (iv) the customer acquiring the product for resale has economic substance apart from that provided by the Company; (v) the Company does not have significant obligations for future performance to directly bring about resale of the product by the customer; and (vi) the amount of future returns can be reasonably estimated. If these factors were to vary, the resulting change could have a material effect on our revenue recognition and on the Company’s results of operations Product Revenue Allowances Product revenue is recognized, net of cash consideration paid to the Company’s customers and wholesalers, for services rendered by wholesalers in accordance with such wholesalers’ agreements and includes a fixed rate per prescription shipped and monthly program management and data fees. These services are not deemed sufficiently separable from the customers' purchase of the product; therefore, they are recorded as a reduction of revenue at the time of revenue recognition. Other product revenue allowances include certain prompt pay discounts and allowances offered to the Company’s customers, program rebates and chargebacks. These product revenue allowances are recognized as a reduction of revenue or as a selling expense at the later of the date at which the related revenue is recognized or the date at which the allowance is offered. Other Revenue License and collaboration revenue is primarily generated through agreements with strategic partners for the development and commercialization of the Company’s product candidates. The terms of the agreements typically include non-refundable upfront fees, funding of research and development activities, payments based upon achievement of certain milestones and royalties on net product sales. In accordance with authoritative guidance, we analyze our multiple element arrangements to determine whether the elements can be separated. We perform our analysis at the inception of the arrangement and as each product or service is delivered. If a product or service is not separable, the combined deliverables are accounted for as a single unit of accounting and revenue is recognized over the performance obligation period. Revenue is recognized when the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred and risk of loss has passed; the seller’s price to the buyer is fixed or determinable; and collectability is reasonably assured. If these factors were to vary the resulting change could have a material effect on our revenue recognition and on our results of operations. Cost of Goods Sold Cost of goods sold includes third may Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include salaries and benefits for research and development personnel, costs associated with clinical trials managed by contract research organizations, and other costs associated with research, development and regulatory activities. Research and development costs may may Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss. Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of Accounting Standards Updates (“ASU”) No. 2014 12, Compensation-Stock Compensation (Topic 718) 12 Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized. Common Stock Warrant Liabilities For warrants that are newly issued or modified and there is a deemed possibility that the Company may Net Income (Loss) per Share The Company computes net income (loss) per share by presenting both basic and diluted earnings (loss) per share (“EPS”). Basic EPS is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing, diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods because their effect would be anti-dilutive. During years ended December 31, 2016, 2015 2014, Year Ended December 31, (in thousands, except per share data) 2016 2015 2014 Net loss $ (13,151 ) $ (18,973 ) $ (15,194 ) Basic shares 9,408 2,784 1,985 Add: shares issued upon assumed exercise of stock options and warrants — — — Diluted shares 9,408 2,784 1,985 Basic EPS $ (1.40 ) $ (6.82 ) $ (7.65 ) Diluted EPS $ (1.40 ) $ (6.82 ) $ (7.65 ) The following outstanding stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive: Year Ended December 31, (in thousands) 2016 2015 2014 Stock options 1,489 388 323 Stock warrants 565 1,458 197 Recent Accounting Pronouncements In May 2014, 2014 09, Revenue from Contracts with Customers 606). August 2015 March, April, May December 2016, may 2014 09 December 15, 2017 December 15, 2016. January 1, 2018 While the Company is still in the process of assessing the potential impact of this new standard on its consolidated financial statements, the Company has identified that transactions which under current guidance are recognized upon shipment from its distributor to the final customers for its major distribution partners will be recognized upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to. As a result, the Company will record contract liabilities for the invoiced amounts that are estimated to be subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, chargebacks, and product returns. The constraint on variable consideration for product returns will be a new estimation resulting from the earlier recognition under the new guidance. The Company has also identified that license and collaboration revenue that is currently accounted for as a combined unit of accounting because products or services are not separable, may may may The Company is still evaluating its major distribution agreements and its license and collaboration agreements and assessing the impact of adoption of the new standard to its consolidated financial statements. The company will continue to monitor additional modifications, clarifications or interpretations undertaken by the FASB that may fourth 2017. In August 2014, 2014 15, Presentation of Financial Statements Going Concern (Subtopic 205 40): December 15, 2016 2014 15 Note1 liquidity In July 2015, 2015 11, Inventory (Topic 330): 2015 11 first 2017, In January 2016, 2016 01, Financial Instruments – Overall (Subtopic 825 10) Recognition and Measurement of Financial Assets and Financial Liabilities first 2018. In February 2016, 2016 02, Leases (Topic 842) Leases (Topic 840) 2016 02 first 2019. In March 2016, 2016 09, Compensation – Stock Compensation (Topic 718): first 2017 In August 2016, 2016 15, Classification of Certain Cash Receipts and Cash Payments (Topic 230), eight 2018. 2016 15 In November 2016, 2016 18, Statement of Cash Flows (Topic 230), 2018. 2016 18

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 3. The Company measures the fair value of financial assets and liabilities based on authoritative guidance that defines fair value, establishes a framework consisting of three The Company’s cash equivalents and investments are classified within Level 1 2 1 2 The Company’s warrant liability is classified within level 3 The following table presents the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2016: Fair Value Measurements Using (in thousands) Balance at December 31, 2016 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash equivalents $ 100 $ 100 $ — $ — Restricted cash held as a certificate of deposit 324 324 — — Deposit held as a certificate of deposit 150 150 — — Total assets $ 574 $ 574 $ — $ — Liabilities Warrant liability $ 1,446 $ — $ — $ 1,446 Total liabilities $ 1,446 $ — $ — $ 1,446 The following table presents the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2015: Fair Value Measurements Using (in thousands) Balance at December 31, 2015 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash equivalents $ 2,385 $ 2,385 $ — $ — Total assets $ 2,385 $ 2,385 $ — $ — Liabilities Warrant liability $ 1,450 $ — $ — $ 1,450 Total liabilities $ 1,450 $ — $ — $ 1,450 For the year ended December 31, 2016, $2.1 10 (in thousands) 2016 2015 Fair value of warrant liability at January 1 $ 1,450 $ 173 Fair value of warrants issued — 1,251 Fair value of warrants transferred (to) from equity upon exercise (2,103 ) 2,175 Increase (decrease) in fair value on exercise date and December 31 2,099 (2,149 ) Fair value of warrant liability at December 31 $ 1,446 $ 1,450

Note 4 - Prepaid Expenses and O

Note 4 - Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Prepaid Expenses and Other Current Assets [Text Block]	NOTE 4. Prepaid expenses and other current assets consisted of the following: (in thousands) December 31, 2016 December 31, 2015 Prepaid sales rebates $ 658 $ — Prepaid outsourced sales team 606 — Rent receivable 165 — Prepaid research and development services 123 — Prepaid rent 120 — Other 294 261 Total prepaid expenses and other current assets $ 1,966 $ 261

Note 5 - Inventory

Note 5 - Inventory	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 5. Inventory consisted of the following: (in thousands) December 31, 2016 December 31, 2015 Raw materials and supplies $ 514 $ 660 Goods in process — 248 Finished goods 555 482 Less: Reserve for excess and obsolete inventory (196 ) (45 ) Total inventory, net $ 873 $ 1,345

Note 6 - Property and Equipment

Note 6 - Property and Equipment	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 6. Property and equipment consisted of the following: (in thousands) December 31, 2016 December 31, 2015 Office and laboratory equipment $ 24 $ 1,528 Furniture and fixtures 153 169 Computer equipment and software 170 122 Production equipment 105 105 Leasehold improvements 68 173 Total property and equipment, at cost 520 2,097 Less: accumulated depreciation and amortization (149 ) (1,702 ) Total property and equipment, net $ 371 $ 395 In the quarter ended September 30, 2016, $66 December 31, 2016. In the quarter ended September 30, 2016, $232 December 31, 2016. In the quarter ended December 31 2016, $13 $4 December 31, 2016. Depreciation and amortization expense was $114 $164 $232 December 31, 2016, 2015 2014,

Note 7 - Accrued Liabilities

Note 7 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 7. Accrued liabilities consisted of the following: (in thousands) December 31, 2016 December 31, 2015 Research and development $ 2 $ 394 Employee payroll and benefits 763 414 Severance pay 250 790 Sales rebates 166 150 Outsourced sales team 333 — Inventory 75 — Other 212 232 Total accrued liabilities $ 1,801 $ 1,980

Note 8 - Related Party Notes Pa

Note 8 - Related Party Notes Payable	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Related Party Notes Payable [Text Block]	NOTE 8. Beginning on December 30, 2015, five (5) $3.0 $199 $71 $20 $1.4 $1.4 two December 30, 2015 January 12, 2016. The proceeds from the Notes were used for general corporate purposes. Minimum March 31, 2016 June, September, December March December 30, 2018, three (3) six (6%) In connection with the Notes, China Kington agreed to act as collateral agent for the benefit of the Lenders, in accordance with the terms of a collateral agency and intercreditor agreement (the “Collateral Agency Agreement”), which was entered into on December 30, 2015 ) December 30, 2015. As consideration to China Kington for facilitating the Loan, the Company agreed to the following: (1) first two (2) $0 three (3) (2) (3) nine (9%) (4) two (5) January 26, 2016 Upon closing the first $11.8 May 6, 2016 $2.5 Upon closing the second $11.8 August 1, 2016, $520 As of December 31, 2016, zero.

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 9. Operating Leases On August 24, 2016, 7,799 eleventh 1150) 2000 94608 February 28, 2022, one five (5) twelve (12) nine (9) first twelve (12) $4.15 ($338,390 three (3%) eleven (11) thirteenth (13 th $4.81 ($450,250 sixty one (61) sixty three (63) 2.16%, first three (3) may $323,658, $151,823 sixtieth (60 th The Company also leases laboratory facilities and office space at Suite 550, 5980 October 21, 2020. July 11, 2016, 16,465 September 8, 2016. October 21, 2020, $40 $66 Rent expense, net was $938 $1,008 $1,045 December 31, 2016, 2015 2014, December 31, 2016: (in thousands) Lease Commitment Year ending December 31: 2017 $ 987 2018 1,083 2019 1,116 2020 1,026 2021 438 Thereafter 75 Total lease commitment $ 4,725 The Company’s monthly rent payments fluctuate under the master lease agreements. In accordance with U.S. GAAP, the Company recognizes rent expense on a straight-line basis, and records deferred rent for the difference between the amounts paid and recorded as expense. At December 31, 2016 2015, $327 $189 Sub-lease rental reimbursement in not deducted from the above table. The Company anticipates collecting $709 $609 $690 $576 December 31, 2017, 2018, 2019, 2020, Directors and Officers Indemnity As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director or officer insurance policy that limits its exposure and may December 31, 2016. In the normal course of business, the Company provides indemnifications of varying scope under its agreements with other companies, typically its clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, it generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third December 31, 2016. Legal Matters From time to time, the Company may December 31, 2016,

Note 10 - Warrant Liability

Note 10 - Warrant Liability	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	NOTE 10. In July 2011, 139,520 $33.25 January 1, 2012 July 5, 2016. 480, 480 January 5, 2012, $66.50 ten fifteen one third In October 2015, March 3, 2015 “2015 twenty two March 3, 2016). October 2015 15 five 2015 “March 2015 June 29, 2011 “July 2011 March 2015 July 2011 $5.00 July 2011 March 6, 2020. July 2011 March 2015 $5.00 $5.00, In October 2015, 492,000 442,802 “October 2015 $5.00 “October 2015 In February 2016, July 2011, March 2015 October 2015 $1.81 The Company evaluated the change in terms of the July 2011 October 27, 2015 $360,821 October 27, 2015 October 27, 2015. The key assumptions used to value the warrants after the modification at October 27, 2015 Assumption Expected price volatility 80.00 % Expected term (in years) 4.36 Risk-free interest rate 1.23 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 2.60 The shares of common stock and warrants were issued separately. Each warrant was exercisable immediately upon issuance and will expire 60 October 2015 $5.00 $2.1 The key assumptions used to value the warrant at December 31, 2016 December 31, 2015 Year Ended December 31, Assumption 2016 2015 Expected price volatility 102.00 % 80.00 % Expected term (in years) 3.18 4.18 Risk-free interest rate 1.51 % 1.58 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 2.55 $ 1.10 In March 2015, ($15.00 ($16.25 March 2015 July 2011 October 2015, March 2015 March 2015 October 27, 2015 $1.8 October 27, 2015 October 27, 2015. The key assumptions used to value the Short-Term and Long-Term Warrants after modification at October 27, 2015 Assumption Expected price volatility 80.00 % Expected term (in years) 4.36 Risk-free interest rate 1.23 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 2.78 The key assumptions used to value the Short-Term Warrants as of December 31, 2016, December 31, 2015 Period Ended Assumption December 31, 2016 December 31, 2015 Expected price volatility 102.00 % 80.00 % Expected term (in years) 3.18 4.18 Risk-free interest rate 1.51 % 1.58 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 2.47 $ 1.16 The key assumptions used to value the Long-Term Warrants as of December 31, 2016, December 31, 2015 Period Ended Assumption December 31, 2016 December 31, 2015 Expected price volatility 102.00 % 80.00 % Expected term (in years) 3.18 4.18 Risk-free interest rate 1.51 % 1.58 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 2.55 $ 1.16 As noted above, the Company issued warrants in connection with the October 2015 October 2015 480, 480 October 27, 2015 $1.3 The key assumptions used to initially value the October 2015 October 27, 2015 Assumption Expected price volatility 75.50 % Expected term (in years) 5.00 Risk-free interest rate 1.38 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 2.82 The key assumptions used to value the warrants as of December 31, 2016, December 31, 2015 Period Ended Assumption December 31, 2016 December 31, 2015 Expected price volatility 96.00 % 77.50 % Expected term (in years) 3.83 4.83 Risk-free interest rate 1.66 % 1.72 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 2.60 $ 1.21 During the third 2016, 3,613,284 3,613,284 July 2011, March 2015 October 2015 $6.9 $1.6 $1.6 During the fourth 2016, 363,523 363,523 October 2011, November 2015 December 2015 $0.9 $0.5 $0.5 The details of all outstanding warrant liability as of December 31, 2016, Shares and dollars in thousands Shares Warrant Liability July 2011 Warrants 49 $ 126 Long-Term Warrants 105 267 Short-Term Warrants 127 312 October 2015 Warrants 284 741 565 $ 1,446

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 11. Amendments to Articles of Incorporation – Reverse Stock Split Effective December 11, 2015, 1 25 December 11, 2015. Preferred Stock Under the Company’s amended articles of incorporation, the Company is authorized to issue of up to 5,000,000 may December 31, 2016 December 31, 2015, Common Stock On March 25, 2014, 224,000 one one 6.25 56,000 $30.00 $39.00 eighteen $6.7 $6.0 $470 $211 On October 16, 2014, “2014 may $10.0 may 3.0% 2014 2014 November 13, 2013. 2014 2014 2014 2014 Pursuant to the 2014 1.3 $1.2 $1.1 $81 On March 6, 2015, 370,993 370,933 278,200 370,933 “March $12.50 $15.00 15 5 $15.00 $16.25 March 6, 2015, may March 2015 $4.7 $4.5 $200 On May 22, 2015, 435,746 217,873 12 “May $15.75, $19.50 May 18, 2015, may May March March 635,000 $7.3 $6.4 $900 six (6%) $408 On October 27, 2015, 492,000 468,280 $5.00 “October 2015 October 2015 October 2015 60 $5.00 October 2015 $2.3 $1.9 $400 In February 2016, three 1,518,567 $2.8 first 696,590 $1.81, five (5%) February 16, 2016, second 696,590 $1.91, February 16, 2016 third 125,387 $1.91, February 16, 2016 may China Kington Asset Management Co. Ltd. served as placement agent in exchange for a commission equal to six (6%) $155 On April 4, 2016, 6,173,299 $0.01 “April 2016 3,086,651 $11.8 4 $1.91, $4.00 five two first May 5, 2016, $7.8 second August 1, 2016, $4.0 4,079,058 April 2016 2,039,530 2,094,241 April 2016 1,047,121 China Kington Asset Management Co. Ltd. served as placement agent in exchange for a commission equal to six (6%) $618 Also on April 4, 2016, may April 2016 April 2016 June 9, 2016 June 20, 2016 333 211943). During the third 2016, $6.6 3,613,284 3,613,284 May 2016 August 2016. six (6%) $338 During the fourth 2016, $0.9 363,523 363,523 six (6%) $32 Stock Warrants In July 2011, 139,520 July 2011 $33.25 July 5, 2016. October 2015, March 6, 2020. December 31, 2016. 10 In March 2015, 278,200 370,933 March 2015 December 31, 2016. 10 In May 2015, 217,873 12 $19.50 November 22, 2015, six one December 31, 2015. 10 In October 2015, 442,800 $5.00 60 $5.00 $5.00, 10 In February 2016, July 2011, March 2015 October 2015 $1.81 In May 2016, 2,039,530 In August 2016, 1,047,121 Effective September 29, 2016, May 18, 2015, $19.50 $3.15 sixteen (16%) September 27, 2016. $270 The following table summarizes information about the Company’s warrants outstanding at December 31, 2016, 2015 2014, three (in thousands) Warrants Weighted- Average Exercise Price Outstanding at December 31, 2013 192 $ 43.00 Warrants granted 55 $ 39.00 Warrants expired (50 ) $ 68.75 Outstanding at December 31, 2014 197 $ 35.23 Warrants granted 1,317 $ 7.40 Warrants expired (56 ) $ 39.00 Outstanding at December 31, 2015 1,458 $ 5.19 Warrants granted 3,087 $ 1.91 Warrants exercised (3,977 ) $ 1.95 Warrants expired (3 ) $ 78.13 Outstanding at December 31, 2016 565 $ 1.81

Note 12 - Equity-based Compensa

Note 12 - Equity-based Compensation	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE 12. Equity Compensation Plans In October 2007, 2007 “2007 2007 40,000 2007 For the years from 2009 2012, 2007 40,000 4% 40,000, 37,427, 37,207 2007 January 2012, 2011 2010, 2013, 40,000 2007 4% 32,646 59,157 2007 January 2014 2013, March 30 th 2015, 82,461 2007 January 2016, 139,449 May 26, 2016, 2007 1,124,826 2007 2,318,486 December 31, 2016, 53,587 2007 Under the terms of the 2007 may 100% 10% 110%. 2007 ten four October 2007 Stock Based Compensation Summary The following table summarizes information about the Company’s stock options and restricted stock outstanding at December 31, 2016, 2015 2014, three (in thousands, except years and per share data) Options Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2013 287 $ 42.00 6.6 422 Options granted 68 $ 22.50 Restricted stock units granted 3 $ — Options exercised (2 ) $ 14.00 Restricted stock units vested (4 ) $ — Options forfeited/cancelled (29 ) $ 36.50 Outstanding at December 31, 2014 323 $ 38.25 6.3 23 Options granted 85 $ 11.20 Restricted stock units granted 16 $ — Options exercised - $ — Restricted stock units vested (6 ) $ — Options forfeited/cancelled (28 ) $ 30.58 Restricted stock units cancelled (2 ) $ — Outstanding at December 31, 2015 388 $ 32.03 6.2 19 Options granted 1,227 $ 2.74 Restricted stock units granted 104 $ — Options exercised - $ — Restricted stock units vested (114 ) $ — Options forfeited/cancelled (116 ) $ 28.27 Restricted stock units cancelled - $ — Outstanding at December 31, 2016 1,489 $ 8.38 8.7 $ 702 Vested and expected to vest at December 31, 2016 1,466 $ 8.45 8.6 $ 691 Vested at December 31, 2016 402 $ 22.45 6.6 $ — Exercisable at December 31, 2016 402 $ 22.45 6.6 $ — For options that have a quoted market price in excess of the exercise price (“in-the-money options”), the aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company’s common stock as quoted on the NYSE MKT as of December 31, 2016. no December 31, 2016. no December 31, 2016 December 31, 2015. $34 December 31, 2014. $0, $4 $32 December 31, 2016, 2015 2014, As of December 31, 2016, $1.5 2.02 Stock Option Awards to Employees and Directors The Company grants options to purchase common stock to its employees and directors at prices equal to or greater than the market value of the stock on the dates the options are granted. The Company has estimated the value of stock option awards as of the date of grant by applying the Black-Scholes-Merton option pricing model using the single-option valuation approach. The application of this valuation model involves assumptions that are judgmental and subjective in nature. See Note 2 During the years ended December 31, 2016, 2015 2014, 1,139,000, 59,000 52,000 The weighted average assumptions used in determining the value of options granted and a summary of the methodology applied to develop each assumption are as follows: Year Ended December 31, Assumption 2016 2015 2014 Expected price volatility 84.47 % 77.22 % 76.88 % Expected term (in years) 7.03 6.8 6.5 Risk-free interest rate 1.57 % 1.76 % 2.06 % Dividend yield 0.00 % 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 2.06 $ 7.35 $ 15.25 Expected Price Volatility Expected Term Risk-Free Interest Rate Dividend Yield Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate. Additionally, during the years ended December 31, 2016, 2015 2014, 64,000, 16,000 2,000 For the years ended December 31, 2016, 2015 2014, $1,489 $1,193 $853 In the second 2015, two 2015 June 2015. three four $185 During the second third 2016, two May 6, 2016 August 24, 2016, three four $58 Stock-Based Awards to Non-Employees During the years ended December 31, 2016, 2015 2014, 89,000, 27,000, 14,000 Year Ended December 31, Assumption 2016 2015 2014 Expected price volatility 87.68 % 83.77 % 79.10 % Expected term (in years) 10.0 9.6 8.6 Risk-free interest rate 1.61 % 2.18 % 2.28 % Dividend yield 0.00 % 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 2.29 $ 7.15 $ 15.25 In addition, the Company granted restricted stock to non-employees totaling 41,000, 500 600 December 31, 2016, 2015 2014, For the years ended December 31, 2016, 2015 2014, $262 $188 $189 In November 2015, December 2016, 2016. December 31, 2015, December 2016. January 2017, In March 2016, March 2016, December 31, 2015 March 2016. Summary of Stock-Based Compensation Expense A summary of the stock-based compensation expense included in results of operations for the option and stock awards discussed above is as follows: Year Ended December 31, (in thousands) 2016 2015 2014 Research and development $ 195 $ 449 $ 376 Sales and Marketing 132 - - General and administrative 1,424 933 666 Total stock-based compensation expense $ 1,751 $ 1,382 $ 1,042 Since the Company has operating losses and net operating loss carryforwards, there are no tax benefits associated with stock-based compensation expense.

Note 13 - License, Collaboratio

Note 13 - License, Collaboration and Distribution Agreements	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	NOTE 13. Virbac In April 2012, In April 2013, 422), may Revenue has been recognized under the agreement as follows: Year Ended December 31, (in thousands) 2016 2015 2014 Materials, Equipment, and Contract Study Costs $ — $ — $ 39 The Company had deferred revenue balances of $246 December 31, 2016, 2015 2014, NeutroPhase Distribution Agreements In January 2012, $312,500. $312,500 January 2013, first December 31, 2014, $625,000 In September 2012, two (1) (2) one one Pursuant to the terms of the Distribution Agreement, Pioneer has the right to distribute NeutroPhase, upon a marketing approval from a Regulatory Authority, in certain territories in Asia (other than China). Upon execution of the Distribution Agreement, the Company received an upfront payment, which was recorded as deferred revenue. Pioneer is also obligated to make certain additional payments to the Company upon receipt of the marketing approval. The Distribution Agreement further provides that Pioneer is entitled to a cumulative purchase discount not to exceed $500,000 Pursuant to the Purchase Agreement, we also received $2.5 one one two (1) 800,000 September 2012; (2) 1,200,000 October 2012, $1.25 $3.5 $2.5 $1 $600,000 In December 2013, two 11 Revenue has been recognized under these agreements as follows: Year Ended December 31, (in thousands) 2016 2015 2014 Amortization of upfront technology access fee $ 94 $ 25 $ 47 Product sales 324 70 161 $ 418 $ 95 $ 208 The Company had deferred revenue balances of $1.0 $1.1 $1.2 December 31, 2016, 2015 2014, On February 7, 2012 $750,000. Revenue has been recognized under this agreement as follows: Year Ended December 31, (in thousands) 2016 2015 2014 Amortization of upfront technology access fee $ 21 $ 5 $ 7 Product sales 332 34 101 $ 353 $ 39 $ 108 The Company had deferred revenue balances of $653 $674 $679 December 31, 2016, 2015 2014, On June 1, 2013 $200,000. Revenue has been recognized under this agreement as follows: Year Ended December 31, (in thousands) 2016 2015 2014 Amortization of upfront technology access fee $ — $ 1 $ 4 Product sales 22 66 104 $ 22 $ 67 $ 108 The Company had deferred revenue balances of $194 $195 $196 December 31, 2016, 2015 2014, Avenova Distribution Agreements In November 2014, January 2015, April 2015, December 2015, During the years ended December 31, 2016, 2015 2014, $7.3 $947 $4 The Company had a deferred revenue balance of $1,924 $24 December 31, 2016 December 31, 2015,

Note 14 - Employee Benefit Plan

Note 14 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	NOTE 14. We have a 401(k) no December 31, 2016.

Note 15 - Income Taxes

Note 15 - Income Taxes	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 15. The federal and state income tax provision is summarized as follows (in thousands): Year Ending December 31 (in thousands) 2016 2015 2014 Current Federal $ — $ — $ — State 2 2 2 Other — — — Total current tax expense 2 2 2 Deferred Federal — — — State — — — Other — — — Total deferred tax expense — — — Income tax provision $ 2 $ 2 $ 2 Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards. The tax effects of significant items comprising the Company's deferred taxes as of December 31, December 31 (in thousands) 2016 2015 Deferred tax assets: Net operating losses $ 34,902 $ 31,464 Accruals 287 403 Deferred revenue 829 954 Stock options 1,894 1,558 Other deferred tax assets 765 652 Total deferred tax assets 38,677 35,031 Deferred tax liabilities: Property and equipment (32 ) (28 ) Total deferred tax liabilities (32 ) (28 ) Valuation allowance (38,645 ) (35,003 ) Net deferred taxes $ — $ — The Company records the tax benefit of net operating loss carryforwards and temporary differences as an asset to the extent that management assesses that realization is "more likely than not." Realization of the future tax benefits is dependent on the Company's ability to generate sufficient taxable income within the carryforward period. Because of the Company's recent history of operating losses, management believes that recognition of the deferred tax assets is currently not likely to be realized and, accordingly, has provided a valuation allowance. The valuation allowance increased by the following amounts (in thousands): 2016 2015 2014 $ 3,642 $ 8,101 $ 6,286 In accordance with ASC 718 Compensation – Stock Compensation $1.1 $0.7 December 31, 2016 NOL and tax credit carryforwards as of December 31, 2016, Expiration Amount Years Net operating losses, federal $ 90,165 2024 - 2036 Net operating losses, state $ 78,219 2028 - 2036 Tax credits, federal $ 1,316 2031 - 2036 Tax credits, state $ 282 do not expire Under U.S. federal tax law, the amount and availability of tax benefits are subject to a variety of interpretations and restrictive tests. Utilization of the NOL carryforwards may 382 1986, may 382, 50 three two may one 382. may 382. The effective tax rate of the Company's provision (benefit) for income taxes differs from the federal statutory rate as follows: Year Ending December 31 (in thousands) 2016 2015 2014 Income tax provision (benefit) at federal statutory rate $ (4,471 ) $ (6,439 ) $ (5,154 ) State tax (157 ) (1,060 ) (818 ) ISO-related expense for GAAP 52 164 144 Change in valuation allowance 3,641 8,101 6,286 Revaluation of warrant liability 806 (731 ) (565 ) Tax credits (31 ) (123 ) (44 ) Other 162 90 153 Total $ 2 $ 2 $ 2 Uncertain Income Tax Positions The Company adopted the provisions of ASC 740 10, Accounting for Uncertainty in Income Taxes January 1, 2007. December 31, 2016 2015 Year ended December 31, (in thousands) 2016 2015 Unrecognized benefit - beginning of period $ 957 $ 811 Gross increases - current period tax positions 17 76 Unrecognized benefit - end of period $ 974 $ 957 The Company’s policy will be to recognize interest and penalties related to income taxes as a component of income tax expense. It is subject to income tax examinations for U.S. incomes taxes and state income taxes from 2004 2006 12

Note 16 - Related Party Transac

Note 16 - Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 16. Related Party Loans See Note 8, two August 1, 2016. Related Party Financing See Note 11, February 2016 April 2016 two Related Party Revenue The Company recognized related party revenues from product sales and license and collaboration fees of $418 $95 $208 December 31 2016, 2015 2014, $75 $0 December 31, 2016 December 31, 2015, 13, one Related Party Expenses The Company recognized related party commission fees of $1.1 $408 $0 December 31 2016, 2015, 2014, 11,

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and are expressed in U.S. dollars.
Reclassification, Policy [Policy Text Block]	Reclassifications Prior period amounts in the accompanying consolidated balance sheets have been reclassified to conform to current period presentation. The reclassifications did not change total assets, total liabilities, or total stockholders’ equity. Additionally, prior period amounts in the accompanying consolidated statement of operations and comprehensive loss and have been reclassified to conform to current period presentation. The reclassifications did not change the net loss or loss per share
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, DermaBay, which was dissolved by the Company in April 2016.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization period for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents and Short-Term Investments The Company considers all highly-liquid instruments with a stated maturity of three December 31, 2016, December 31, 2015, three The Company classifies all highly-liquid investments with a stated maturity of greater than three twelve No December 31, 2016 December 31, 2015, no
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk, Major Partners and Customers, and Suppliers Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits of cash and cash equivalents with three Deposits in these banks may During the years ended December 31, 2016 2015 three December 31, 2014 one As of December 31, 2016, December 31, 2015 December 31, 2014 10% Year Ended December 31, Major distribution or collaboration partner 2016 2015 2014 Distributer A 20 % * * Distributer B 22 % * * Distributer C 16 % * * Collaborator D * * 15 % *Not greater than 10% As of December 31, 2016, December 31, 2015 10% Year Ended December 31, Major distribution or collaboration partner 2016 2015 Distributer A 31 % 11 % Distributer B 24 % * Distributer C 22 % 36 % *Not greater than 10% The Company relies on two third third may
Fair Value Measurement, Policy [Policy Text Block]	Fair Value of Financial Assets and Liabilities Financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Our warrant liability is carried at fair value. The Company measures the fair value of financial assets and liabilities based on U.S. GAAP guidance, which defines fair value, establishes a framework for measuring fair value, and requires disclosures about fair value measurements. Under U.S. GAAP, fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is also established, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three may Level 1 Level 2 Level 3
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it unlikely a specific invoice will be collected. Management identifies amounts due that are in dispute and it believes are unlikely to be collected at the end of 2016. December 31, 2016 December 31, 2015, $10 $40 120
Inventory, Policy [Policy Text Block]	Inventory Inventory is comprised of (1) (2) (3) December 31, 2016 2015, $196 $45 Inventory is stated at the lower of cost or market value determined by the first first
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three seven seven The costs of normal maintenance, repairs, and minor replacements are charged to operations when incurred. In September 2016, $66 third 2016, December 31, 2016.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company accounts for long-lived assets in accordance with U.S. GAAP, which requires that companies consider whether events or changes in facts and circumstances, both internally and externally, may first 2016, $91 first 2016, December 31, 2016.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) ASC 220, Comprehensive Income,
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company sells products through a limited number of distributors and via its webstore. The Company generally records product sales upon shipment to the final customer for its webstore sales and upon shipment from its distributor to the final customers for its major distribution partners. The Company recognizes product revenue when: (i) persuasive evidence that a sale arrangement exists; (ii) delivery has occurred and title has passed; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. Revenue from sales transactions where the customer has the right to return the product is recognized at the time of sale only if: (i) the Company’s price to the customer is substantially fixed or determinable at the date of sale; (ii) the customer has paid the Company, or the customer is obligated to pay the Company and the obligation is not contingent on resale of the product; (iii) the customer's obligation to the Company would not be changed in the event of theft or physical destruction or damage of the product; (iv) the customer acquiring the product for resale has economic substance apart from that provided by the Company; (v) the Company does not have significant obligations for future performance to directly bring about resale of the product by the customer; and (vi) the amount of future returns can be reasonably estimated. If these factors were to vary, the resulting change could have a material effect on our revenue recognition and on the Company’s results of operations Product Revenue Allowances Product revenue is recognized, net of cash consideration paid to the Company’s customers and wholesalers, for services rendered by wholesalers in accordance with such wholesalers’ agreements and includes a fixed rate per prescription shipped and monthly program management and data fees. These services are not deemed sufficiently separable from the customers' purchase of the product; therefore, they are recorded as a reduction of revenue at the time of revenue recognition. Other product revenue allowances include certain prompt pay discounts and allowances offered to the Company’s customers, program rebates and chargebacks. These product revenue allowances are recognized as a reduction of revenue or as a selling expense at the later of the date at which the related revenue is recognized or the date at which the allowance is offered. Other Revenue License and collaboration revenue is primarily generated through agreements with strategic partners for the development and commercialization of the Company’s product candidates. The terms of the agreements typically include non-refundable upfront fees, funding of research and development activities, payments based upon achievement of certain milestones and royalties on net product sales. In accordance with authoritative guidance, we analyze our multiple element arrangements to determine whether the elements can be separated. We perform our analysis at the inception of the arrangement and as each product or service is delivered. If a product or service is not separable, the combined deliverables are accounted for as a single unit of accounting and revenue is recognized over the performance obligation period. Revenue is recognized when the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred and risk of loss has passed; the seller’s price to the buyer is fixed or determinable; and collectability is reasonably assured. If these factors were to vary the resulting change could have a material effect on our revenue recognition and on our results of operations.
Cost of Sales, Policy [Policy Text Block]	Cost of Goods Sold Cost of goods sold includes third may
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include salaries and benefits for research and development personnel, costs associated with clinical trials managed by contract research organizations, and other costs associated with research, development and regulatory activities. Research and development costs may may
Legal Costs, Policy [Policy Text Block]	Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of Accounting Standards Updates (“ASU”) No. 2014 12, Compensation-Stock Compensation (Topic 718) 12
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized.
Warrant Liabilities [Policy Text Block]	Common Stock Warrant Liabilities For warrants that are newly issued or modified and there is a deemed possibility that the Company may
Earnings Per Share, Policy [Policy Text Block]	Net Income (Loss) per Share The Company computes net income (loss) per share by presenting both basic and diluted earnings (loss) per share (“EPS”). Basic EPS is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing, diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods because their effect would be anti-dilutive. During years ended December 31, 2016, 2015 2014, Year Ended December 31, (in thousands, except per share data) 2016 2015 2014 Net loss $ (13,151 ) $ (18,973 ) $ (15,194 ) Basic shares 9,408 2,784 1,985 Add: shares issued upon assumed exercise of stock options and warrants — — — Diluted shares 9,408 2,784 1,985 Basic EPS $ (1.40 ) $ (6.82 ) $ (7.65 ) Diluted EPS $ (1.40 ) $ (6.82 ) $ (7.65 ) The following outstanding stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive: Year Ended December 31, (in thousands) 2016 2015 2014 Stock options 1,489 388 323 Stock warrants 565 1,458 197
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, 2014 09, Revenue from Contracts with Customers 606). August 2015 March, April, May December 2016, may 2014 09 December 15, 2017 December 15, 2016. January 1, 2018 While the Company is still in the process of assessing the potential impact of this new standard on its consolidated financial statements, the Company has identified that transactions which under current guidance are recognized upon shipment from its distributor to the final customers for its major distribution partners will be recognized upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to. As a result, the Company will record contract liabilities for the invoiced amounts that are estimated to be subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, chargebacks, and product returns. The constraint on variable consideration for product returns will be a new estimation resulting from the earlier recognition under the new guidance. The Company has also identified that license and collaboration revenue that is currently accounted for as a combined unit of accounting because products or services are not separable, may may may The Company is still evaluating its major distribution agreements and its license and collaboration agreements and assessing the impact of adoption of the new standard to its consolidated financial statements. The company will continue to monitor additional modifications, clarifications or interpretations undertaken by the FASB that may fourth 2017. In August 2014, 2014 15, Presentation of Financial Statements Going Concern (Subtopic 205 40): December 15, 2016 2014 15 Note1 liquidity In July 2015, 2015 11, Inventory (Topic 330): 2015 11 first 2017, In January 2016, 2016 01, Financial Instruments – Overall (Subtopic 825 10) Recognition and Measurement of Financial Assets and Financial Liabilities first 2018. In February 2016, 2016 02, Leases (Topic 842) Leases (Topic 840) 2016 02 first 2019. In March 2016, 2016 09, Compensation – Stock Compensation (Topic 718): first 2017 In August 2016, 2016 15, Classification of Certain Cash Receipts and Cash Payments (Topic 230), eight 2018. 2016 15 In November 2016, 2016 18, Statement of Cash Flows (Topic 230), 2018. 2016 18

Note 2 - Summary of Significa25

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Year Ended December 31, Major distribution or collaboration partner 2016 2015 2014 Distributer A 20 % * * Distributer B 22 % * * Distributer C 16 % * * Collaborator D * * 15 % Year Ended December 31, Major distribution or collaboration partner 2016 2015 Distributer A 22 % 36 % Distributer B 24 % 11 % Distributer C 31 % *
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, (in thousands, except per share data) 2016 2015 2014 Net loss $ (13,151 ) $ (18,973 ) $ (15,194 ) Basic shares 9,408 2,784 1,985 Add: shares issued upon assumed exercise of stock options and warrants — — — Diluted shares 9,408 2,784 1,985 Basic EPS $ (1.40 ) $ (6.82 ) $ (7.65 ) Diluted EPS $ (1.40 ) $ (6.82 ) $ (7.65 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, (in thousands) 2016 2015 2014 Stock options 1,489 388 323 Stock warrants 565 1,458 197

Note 3 - Fair Value Measureme26

Note 3 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements Using (in thousands) Balance at December 31, 2016 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash equivalents $ 100 $ 100 $ — $ — Restricted cash held as a certificate of deposit 324 324 — — Deposit held as a certificate of deposit 150 150 — — Total assets $ 574 $ 574 $ — $ — Liabilities Warrant liability $ 1,446 $ — $ — $ 1,446 Total liabilities $ 1,446 $ — $ — $ 1,446 Fair Value Measurements Using (in thousands) Balance at December 31, 2015 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash equivalents $ 2,385 $ 2,385 $ — $ — Total assets $ 2,385 $ 2,385 $ — $ — Liabilities Warrant liability $ 1,450 $ — $ — $ 1,450 Total liabilities $ 1,450 $ — $ — $ 1,450
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	(in thousands) 2016 2015 Fair value of warrant liability at January 1 $ 1,450 $ 173 Fair value of warrants issued — 1,251 Fair value of warrants transferred (to) from equity upon exercise (2,103 ) 2,175 Increase (decrease) in fair value on exercise date and December 31 2,099 (2,149 ) Fair value of warrant liability at December 31 $ 1,446 $ 1,450

Note 4 - Prepaid Expenses and27

Note 4 - Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	(in thousands) December 31, 2016 December 31, 2015 Prepaid sales rebates $ 658 $ — Prepaid outsourced sales team 606 — Rent receivable 165 — Prepaid research and development services 123 — Prepaid rent 120 — Other 294 261 Total prepaid expenses and other current assets $ 1,966 $ 261

Note 5 - Inventory (Tables)

Note 5 - Inventory (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Inventory, Current [Table Text Block]	(in thousands) December 31, 2016 December 31, 2015 Raw materials and supplies $ 514 $ 660 Goods in process — 248 Finished goods 555 482 Less: Reserve for excess and obsolete inventory (196 ) (45 ) Total inventory, net $ 873 $ 1,345

Note 6 - Property and Equipme29

Note 6 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Property, Plant and Equipment [Table Text Block]	(in thousands) December 31, 2016 December 31, 2015 Office and laboratory equipment $ 24 $ 1,528 Furniture and fixtures 153 169 Computer equipment and software 170 122 Production equipment 105 105 Leasehold improvements 68 173 Total property and equipment, at cost 520 2,097 Less: accumulated depreciation and amortization (149 ) (1,702 ) Total property and equipment, net $ 371 $ 395

Note 7 - Accrued Liabilities (T

Note 7 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	(in thousands) December 31, 2016 December 31, 2015 Research and development $ 2 $ 394 Employee payroll and benefits 763 414 Severance pay 250 790 Sales rebates 166 150 Outsourced sales team 333 — Inventory 75 — Other 212 232 Total accrued liabilities $ 1,801 $ 1,980

Note 9 - Commitments and Cont31

Note 9 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	(in thousands) Lease Commitment Year ending December 31: 2017 $ 987 2018 1,083 2019 1,116 2020 1,026 2021 438 Thereafter 75 Total lease commitment $ 4,725

Note 10 - Warrant Liability (Ta

Note 10 - Warrant Liability (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Derivative Instruments [Table Text Block]	Assumption Expected price volatility 80.00 % Expected term (in years) 4.36 Risk-free interest rate 1.23 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 2.60 Year Ended December 31, Assumption 2016 2015 Expected price volatility 102.00 % 80.00 % Expected term (in years) 3.18 4.18 Risk-free interest rate 1.51 % 1.58 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 2.55 $ 1.10 Assumption Expected price volatility 80.00 % Expected term (in years) 4.36 Risk-free interest rate 1.23 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 2.78 Period Ended Assumption December 31, 2016 December 31, 2015 Expected price volatility 102.00 % 80.00 % Expected term (in years) 3.18 4.18 Risk-free interest rate 1.51 % 1.58 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 2.47 $ 1.16 Period Ended Assumption December 31, 2016 December 31, 2015 Expected price volatility 102.00 % 80.00 % Expected term (in years) 3.18 4.18 Risk-free interest rate 1.51 % 1.58 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 2.55 $ 1.16 Assumption Expected price volatility 75.50 % Expected term (in years) 5.00 Risk-free interest rate 1.38 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 2.82 Period Ended Assumption December 31, 2016 December 31, 2015 Expected price volatility 96.00 % 77.50 % Expected term (in years) 3.83 4.83 Risk-free interest rate 1.66 % 1.72 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 2.60 $ 1.21
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	(in thousands) Warrants Weighted- Average Exercise Price Outstanding at December 31, 2013 192 $ 43.00 Warrants granted 55 $ 39.00 Warrants expired (50 ) $ 68.75 Outstanding at December 31, 2014 197 $ 35.23 Warrants granted 1,317 $ 7.40 Warrants expired (56 ) $ 39.00 Outstanding at December 31, 2015 1,458 $ 5.19 Warrants granted 3,087 $ 1.91 Warrants exercised (3,977 ) $ 1.95 Warrants expired (3 ) $ 78.13 Outstanding at December 31, 2016 565 $ 1.81
July 2011, Long-term, Short-term, and October 2015 Warrants [Member]
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Shares and dollars in thousands Shares Warrant Liability July 2011 Warrants 49 $ 126 Long-Term Warrants 105 267 Short-Term Warrants 127 312 October 2015 Warrants 284 741 565 $ 1,446

Note 11 - Stockholders' Equit33

Note 11 - Stockholders' Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	(in thousands) Warrants Weighted- Average Exercise Price Outstanding at December 31, 2013 192 $ 43.00 Warrants granted 55 $ 39.00 Warrants expired (50 ) $ 68.75 Outstanding at December 31, 2014 197 $ 35.23 Warrants granted 1,317 $ 7.40 Warrants expired (56 ) $ 39.00 Outstanding at December 31, 2015 1,458 $ 5.19 Warrants granted 3,087 $ 1.91 Warrants exercised (3,977 ) $ 1.95 Warrants expired (3 ) $ 78.13 Outstanding at December 31, 2016 565 $ 1.81

Note 12 - Equity-based Compen34

Note 12 - Equity-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	(in thousands, except years and per share data) Options Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2013 287 $ 42.00 6.6 422 Options granted 68 $ 22.50 Restricted stock units granted 3 $ — Options exercised (2 ) $ 14.00 Restricted stock units vested (4 ) $ — Options forfeited/cancelled (29 ) $ 36.50 Outstanding at December 31, 2014 323 $ 38.25 6.3 23 Options granted 85 $ 11.20 Restricted stock units granted 16 $ — Options exercised - $ — Restricted stock units vested (6 ) $ — Options forfeited/cancelled (28 ) $ 30.58 Restricted stock units cancelled (2 ) $ — Outstanding at December 31, 2015 388 $ 32.03 6.2 19 Options granted 1,227 $ 2.74 Restricted stock units granted 104 $ — Options exercised - $ — Restricted stock units vested (114 ) $ — Options forfeited/cancelled (116 ) $ 28.27 Restricted stock units cancelled - $ — Outstanding at December 31, 2016 1,489 $ 8.38 8.7 $ 702 Vested and expected to vest at December 31, 2016 1,466 $ 8.45 8.6 $ 691 Vested at December 31, 2016 402 $ 22.45 6.6 $ — Exercisable at December 31, 2016 402 $ 22.45 6.6 $ —
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, Assumption 2016 2015 2014 Expected price volatility 84.47 % 77.22 % 76.88 % Expected term (in years) 7.03 6.8 6.5 Risk-free interest rate 1.57 % 1.76 % 2.06 % Dividend yield 0.00 % 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 2.06 $ 7.35 $ 15.25
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Year Ended December 31, (in thousands) 2016 2015 2014 Research and development $ 195 $ 449 $ 376 Sales and Marketing 132 - - General and administrative 1,424 933 666 Total stock-based compensation expense $ 1,751 $ 1,382 $ 1,042
Nonemployees [Member]
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, Assumption 2016 2015 2014 Expected price volatility 87.68 % 83.77 % 79.10 % Expected term (in years) 10.0 9.6 8.6 Risk-free interest rate 1.61 % 2.18 % 2.28 % Dividend yield 0.00 % 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 2.29 $ 7.15 $ 15.25

Note 13 - License, Collaborat35

Note 13 - License, Collaboration and Distribution Agreements (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	Year Ended December 31, (in thousands) 2016 2015 2014 Materials, Equipment, and Contract Study Costs $ — $ — $ 39 Year Ended December 31, (in thousands) 2016 2015 2014 Amortization of upfront technology access fee $ 94 $ 25 $ 47 Product sales 324 70 161 $ 418 $ 95 $ 208 Year Ended December 31, (in thousands) 2016 2015 2014 Amortization of upfront technology access fee $ 21 $ 5 $ 7 Product sales 332 34 101 $ 353 $ 39 $ 108 Year Ended December 31, (in thousands) 2016 2015 2014 Amortization of upfront technology access fee $ — $ 1 $ 4 Product sales 22 66 104 $ 22 $ 67 $ 108

Note 15 - Income Taxes (Tables)

Note 15 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ending December 31 (in thousands) 2016 2015 2014 Current Federal $ — $ — $ — State 2 2 2 Other — — — Total current tax expense 2 2 2 Deferred Federal — — — State — — — Other — — — Total deferred tax expense — — — Income tax provision $ 2 $ 2 $ 2
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31 (in thousands) 2016 2015 Deferred tax assets: Net operating losses $ 34,902 $ 31,464 Accruals 287 403 Deferred revenue 829 954 Stock options 1,894 1,558 Other deferred tax assets 765 652 Total deferred tax assets 38,677 35,031 Deferred tax liabilities: Property and equipment (32 ) (28 ) Total deferred tax liabilities (32 ) (28 ) Valuation allowance (38,645 ) (35,003 ) Net deferred taxes $ — $ —
Summary of Valuation Allowance [Table Text Block]	2016 2015 2014 $ 3,642 $ 8,101 $ 6,286
Summary of Tax Credit Carryforwards [Table Text Block]	Expiration Amount Years Net operating losses, federal $ 90,165 2024 - 2036 Net operating losses, state $ 78,219 2028 - 2036 Tax credits, federal $ 1,316 2031 - 2036 Tax credits, state $ 282 do not expire
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ending December 31 (in thousands) 2016 2015 2014 Income tax provision (benefit) at federal statutory rate $ (4,471 ) $ (6,439 ) $ (5,154 ) State tax (157 ) (1,060 ) (818 ) ISO-related expense for GAAP 52 164 144 Change in valuation allowance 3,641 8,101 6,286 Revaluation of warrant liability 806 (731 ) (565 ) Tax credits (31 ) (123 ) (44 ) Other 162 90 153 Total $ 2 $ 2 $ 2
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Year ended December 31, (in thousands) 2016 2015 Unrecognized benefit - beginning of period $ 957 $ 811 Gross increases - current period tax positions 17 76 Unrecognized benefit - end of period $ 974 $ 957

Note 1 - Organization (Details

Note 1 - Organization (Details Textual)	Dec. 11, 2015	Aug. 31, 2007	Dec. 31, 2016	Dec. 31, 2015
Number of Subsidiaries		2
Number of Operating Segments			1	4
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	25		25

Note 2 - Summary of Significa38

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Sep. 30, 2016	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015
Inventory Valuation Reserves			$ 196	$ 45
Impairment of Long-Lived Assets Held-for-use				0
Short-term Investments			$ 0	0
General and Administrative Expense [Member]
Impairment of Leasehold	$ 66
Research and Development Expense [Member]
Impairment of Long-Lived Assets Held-for-use		$ 91
Computer Equipment and Software [Member]
Property, Plant and Equipment, Useful Life			3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life			7 years
Minimum [Member] | Equipment [Member]
Property, Plant and Equipment, Useful Life			5 years
Maximum [Member] | Equipment [Member]
Property, Plant and Equipment, Useful Life			7 years
Maximum [Member] | Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life			7 years
Allowance for Doubtful Accounts [Member]
Valuation Allowances and Reserves, Balance			$ 10	$ 40

Note 2 - Summary of Significa39

Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable From Major Distribution Partners and Customers (Details) - Customer Concentration Risk [Member]		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015
Sales Revenue, Net [Member] | Distributor A [Member]
Distributer A		20.00%
Sales Revenue, Net [Member] | Distributor B [Member]
Distributer A		22.00%
Sales Revenue, Net [Member] | Distributor C [Member]
Distributer A		16.00%
Sales Revenue, Net [Member] | Collaborator D [Member]
Distributer A	[1]		15.00%
Accounts Receivable [Member] | Distributor A [Member]
Distributer A		22.00%	36.00%
Accounts Receivable [Member] | Distributor B [Member]
Distributer A		24.00%	11.00%	[1]
Accounts Receivable [Member] | Distributor C [Member]
Distributer A		31.00%
[1]	Not greater than 10%.

Note 2 - Summary of Significa40

Note 2 - Summary of Significant Accounting Policies - Reconciliation Between Basic Net Income (Loss) Per Share and Diluted Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Net loss	$ (13,151)	$ (18,973)	$ (15,194)
Basic shares (in shares)	9,408	2,784	1,985
Diluted shares (in shares)	9,408	2,784	1,985
Basic EPS (in dollars per share)	$ (1.40)	$ (6.82)	$ (7.65)
Diluted EPS (in dollars per share)	$ (1.40)	$ (6.82)	$ (7.65)

Note 2 - Summary of Significa41

Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded from the Diluted Net Loss Per Share Computation (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Employee Stock Option [Member]
Stock options (in shares)	1,489	388	323
Warrant [Member]
Stock options (in shares)	565	1,458	197

Note 3 - Fair Value Measureme42

Note 3 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Other Nonoperating Gains (Losses)	$ (2,099)	$ 2,149	$ 1,664

Note 3 - Fair Value Measureme43

Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Assets
Cash equivalents	$ 100	$ 2,385
Restricted cash held as a certificate of deposit	324
Deposit held as a certificate of deposit	150
Total assets	574	2,385
Liabilities
Warrant liability	1,446	1,450
Total liabilities	1,446	1,450
Fair Value, Inputs, Level 1 [Member]
Assets
Cash equivalents	100	2,385
Restricted cash held as a certificate of deposit	324
Deposit held as a certificate of deposit	150
Total assets	574	2,385
Liabilities
Warrant liability
Total liabilities
Fair Value, Inputs, Level 2 [Member]
Assets
Cash equivalents
Restricted cash held as a certificate of deposit
Deposit held as a certificate of deposit
Total assets
Liabilities
Warrant liability
Total liabilities
Fair Value, Inputs, Level 3 [Member]
Assets
Cash equivalents
Restricted cash held as a certificate of deposit
Deposit held as a certificate of deposit
Total assets
Liabilities
Warrant liability	1,446	1,450
Total liabilities	$ 1,446	$ 1,450

Note 3 - Fair Value Measureme44

Note 3 - Fair Value Measurements - Fair Value of Warrant Liability (Details) - Warrant Liability [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair value of warrant liability	$ 1,450	$ 173
Fair value of warrants issued		1,251
Fair value of warrants transferred (to) from equity upon exercise	(2,103)	2,175
Increase in fair value	2,099	(2,149)
Fair value of warrant liability	$ 1,446	$ 1,450

Note 4 - Prepaid Expenses and45

Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Prepaid sales rebates	$ 658
Prepaid outsourced sales team	606
Rent receivable	165
Prepaid research and development services	123
Prepaid rent	120
Other	294	261
Total prepaid expenses and other current assets	$ 1,966	$ 261

Note 5 - Inventory - Summary of

Note 5 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Raw materials and supplies	$ 514	$ 660
Goods in process		248
Finished goods	555	482
Less: Reserve for excess and obsolete inventory	(196)	(45)
Total inventory, net	$ 873	$ 1,345

Note 6 - Property and Equipme47

Note 6 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property		$ 219	$ 1	$ 54
Tangible Asset Impairment Charges		70
Depreciation, Depletion and Amortization		114	$ 164	$ 232
Damaged, Unusable and Full Depreciated Properly and Equipment [Member]
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property		(13)
General and Administrative Expense [Member]
Impairment of Leasehold	$ 66
General and Administrative Expense [Member] | Damaged, Unusable and Full Depreciated Properly and Equipment [Member]
Tangible Asset Impairment Charges		4
General and Administrative Expense [Member] | Sublease Agreement [Member]
Impairment of Leasehold		66
Research and Development Expense [Member] | Laboratory Equipment [Member]
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property		$ 232

Note 6 - Property and Equipme48

Note 6 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property and equipment, at cost	$ 520	$ 2,097
Less: accumulated depreciation and amortization	(149)	(1,702)
Total property and equipment, net	371	395
Equipment [Member]
Property and equipment, at cost	24	1,528
Furniture and Fixtures [Member]
Property and equipment, at cost	153	169
Computer Equipment and Software [Member]
Property and equipment, at cost	170	122
Production Equipment [Member]
Property and equipment, at cost	105	105
Leasehold Improvements [Member]
Property and equipment, at cost	$ 68	$ 173

Note 7 - Accrued Liabilities -

Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Research and development	$ 2	$ 394
Employee payroll and benefits	763	414
Severance pay	250	790
Sales rebates	166	150
Outsourced sales team	333
Inventory	75
Other	212	232
Total accrued liabilities	$ 1,801	$ 1,980

Note 8 - Related Party Notes 50

Note 8 - Related Party Notes Payable (Details Textual) - USD ($)	Aug. 01, 2016	May 06, 2016	Jan. 12, 2016	Dec. 30, 2015	Dec. 31, 2016
Proceeds from Issuance of Private Placement	$ 11,800,000	$ 11,800,000
Private Placement [Member]
Repayments of Related Party Debt	$ 520,000	$ 2,500,000
Notes [Member] | China Kingston [Member]
Loan Facilitation Consideration Lead Financings, Three Consecutive Months Cash Flow, Minimum				$ 0
Loan Facilitation Consideration Financing Provided By Board and Management on Next Financing, Percentage				9.00%
Loan Facilitation Consideration, Number of New Appointments to Board				2
Notes [Member] | Lenders [Member]
Proceeds from Related Party Debt				$ 3,000,000
Related Party Transaction, Rate				6.00%
Due to Related Parties					$ 0
Promissory Note 1 [Member] | Board of Directors Chairman [Member]
Proceeds from Related Party Debt				$ 199,000
Promissory Note 2 [Member] | Director [Member]
Proceeds from Related Party Debt				71,000
Promissory Note 3 [Member] | Director [Member]
Proceeds from Related Party Debt				20,000
Promissory Note 4 [Member] | Pioneer Pharma Co. [Member]
Proceeds from Related Party Debt				$ 1,400,000
Promissory Note 5 [Member] | Mr. Fu [Member]
Proceeds from Related Party Debt			$ 1,400,000
Debt Instrument, Term			3 years

Note 9 - Commitments and Cont51

Note 9 - Commitments and Contingencies (Details Textual)	Aug. 24, 2016USD ($)ft²	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Jul. 11, 2016ft²
Area of Property in Sublease Agreement | ft²						16,465
Operating Leases, Rent Expense			$ 938,000	$ 1,008,000	$ 1,045,000
Deferred Rent Credit, Noncurrent			327,000	$ 189,000
General and Administrative Expense [Member]
Noncash Loss on Sublease			40,000
Impairment of Leasehold		$ 66,000
Sublease Agreement [Member]
Operating Leases, Future Minimum Payments Receivable, Current			709,000
Operating Leases, Future Minimum Payments Receivable, in Two Years			609,000
Operating Leases, Future Minimum Payments Receivable, in Three Years			690,000
Operating Leases, Future Minimum Payments Receivable, in Four Years			576,000
Sublease Agreement [Member] | General and Administrative Expense [Member]
Impairment of Leasehold			$ 66,000
KBSIII Towers [Member]
Lessee Leasing Arrangements, Operating Leases, Square Feet of Property | ft²	7,799
Lessee Leasing Arrangements, Operating Leases, Renewal Term	5 years
Lessee Leasing Arrangements, Operating Leases, Earliest Period Prior to Expiration of Current Term to Renew Lease	1 year
Lessee Leasing Arrangements, Operating Leases, Latest Period Prior to Expiration of Current Term to Renew Lease	270 days
Lessee Leasing Arrangements, Operating Leases, Term of Contract	5 years 90 days
Lessee Leasing Arrangements, Operating Leases, Direct Expenses of Premises, Percentage	2.16%
Lessee Leasing Arrangements, Operating Leases, Abatement Term for Monthly Base Rental Payments	90 days
KBSIII Towers [Member] | Other Assets [Member]
Lessee Leasing Arrangements, Operating Leases, Standby Letter of Credit, Initial Amount	$ 323,658
KBSIII Towers [Member] | First 12 Months of Operating Lease [Member]
Lessee Leasing Arrangements, Operating Leases, Monthly Base Rental Rate	4.15
Lessee Leasing Arrangement, Operating Leases, Annual Base Rental Rate Amount	$ 338,390
KBSIII Towers [Member] | Every 11 Months of Operating Lease [Member]
Lessee Leasing Arrangements, Operating Leases, Increase in Monthly Base Rental Rate, Percentage	3.00%
KBSIII Towers [Member] | First 61 to 63 Months of Operating Lease [Member] | Maximum [Member]
Lessee Leasing Arrangements, Operating Leases, Monthly Base Rental Rate	4.81
Lessee Leasing Arrangement, Operating Leases, Annual Base Rental Rate Amount	$ 450,250
KBSIII Towers [Member] | Last Day of 60th Month of Operating Lease [Member] | Maximum [Member]
Lessee Leasing Arrangements, Operating Leases, Standby Letter of Credit, Reduced Amount	$ 151,823

Note 9 - Commitments and Cont52

Note 9 - Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2016USD ($)
2,017	$ 987
2,018	1,083
2,019	1,116
2,020	1,026
2,021	438
Thereafter	75
Total lease commitment	$ 4,725

Note 10 - Warrant Liability (De

Note 10 - Warrant Liability (Details Textual) - USD ($)	Aug. 01, 2016	May 05, 2016	Apr. 04, 2016	Feb. 16, 2016	Oct. 27, 2015	Oct. 27, 2015	Oct. 22, 2015	May 22, 2015	Mar. 03, 2015	Oct. 31, 2015	Jul. 31, 2011	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Sep. 29, 2016	Sep. 28, 2016	May 31, 2016	Feb. 29, 2016	Mar. 06, 2015	Mar. 25, 2014	Dec. 31, 2013	Jan. 05, 2012
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Warrants Issued											139,520
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 33.25	$ 1,810		$ 1,810	$ 5,190	$ 35,230	$ 3.15	$ 19.50				$ 39	$ 43,000
Minimum Common Stock Closing Bid Price Per Share																								$ 66.50
Warrant Expiration Term						5 years				5 years
Stock Issued During Period, Shares, New Issues				1,518,567		492,000		435,746
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												363,523	3,613,284	363,523					2,039,530			56,000
Warrants and Rights Outstanding												$ 1,446,000		$ 1,446,000	$ 1,450,000
Proceeds from Warrant Exercises												900,000	$ 6,600,000
Other Nonoperating Gains (Losses)														(2,099,000)	$ 2,149,000	$ 1,664,000
Fair Market Value of Warrants Transferred to Equity Upon Exercise														2,103,000
Short-term Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 15
Warrants and Rights Outstanding												312,000		312,000
Long-term Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 16.25
Warrants and Rights Outstanding												$ 267,000		$ 267,000
The 2011 and March 2015 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 5
Warrants to be Exercised at Lower Price Stock Price Trigger							5
Class of Warrant or Right Price Protection Provision Exchangeable Securities Exercise Price Trigger							$ 5
Warrants and Rights Outstanding					$ 1,800,000	$ 1,800,000
July 2011, March 2015, and October 2015 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												363,523	3,613,284	363,523
Class of Warrant or Right, Exercised During Period												363,523	3,613,284
Proceeds from Warrant Exercises												$ 900,000	$ 6,900,000
Other Nonoperating Gains (Losses)												500,000	1,600,000
Fair Market Value of Warrants Transferred to Equity Upon Exercise												500,000	$ 1,600,000
The 2011 Warrants [Member]
Warrants and Rights Outstanding					$ 360,821	$ 360,821						$ 126,000		$ 126,000
Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.91
Length of Notice Required to Investors Prior to Issuance of New Securities							2 days		20 days
Warrant Expiration Term			4 years
Stock Issued During Period, Shares, New Issues	2,094,241	4,079,058	6,173,299
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,047,121	2,039,530	3,086,651																		370,933
Private Placement [Member] | Short-term Warrants [Member]
Warrant Expiration Term							1 year 90 days
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																					370,933
Private Placement [Member] | Long-term Warrants [Member]
Warrant Expiration Term							5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																					278,200
Underwriting Agreement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 5	$ 5
Warrant Expiration Term					60 years
Stock Issued During Period, Shares, New Issues					492,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					442,802	442,802
Warrants and Rights Outstanding					$ 1,300,000	$ 1,300,000
Proceeds from Issuance of Stock and Warrants					$ 2,100,000
Mr. Fu [Member]
Stock Issued During Period, Shares, New Issues				696,590
Mr. Fu [Member] | July 2011, March 2015, and October 2015 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights																				$ 1.81

Note 10 - Warrant Liability - T

Note 10 - Warrant Liability - The Key Assumptions Used to Value the Warrants (Details) - Warrant Fair Value [Member] - $ / shares	Oct. 27, 2015	Dec. 31, 2016	Dec. 31, 2015
The 2011 Warrants [Member]
Expected price volatility	80.00%	102.00%	80.00%
Expected term (in years) (Year)	4 years 131 days	3 years 65 days	4 years 65 days
Risk-free interest rate	1.23%	1.51%	1.58%
Dividend yield	0.00%	0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)	$ 2.60	$ 2.55	$ 1.10
Expected price volatility	80.00%	102.00%	80.00%
Expected term (in years) (Year)	4 years 131 days	3 years 65 days	4 years 65 days
Risk-free interest rate	1.23%	1.51%	1.58%
Dividend yield	0.00%	0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)	$ 2.60	$ 2.55	$ 1.10
Short-term and Long-term Warrants [Member]
Expected price volatility	80.00%
Expected term (in years) (Year)	4 years 131 days
Risk-free interest rate	1.23%
Dividend yield	0.00%
Weighted-average fair value of warrants (in dollars per share)	$ 2.78
Expected price volatility	80.00%
Expected term (in years) (Year)	4 years 131 days
Risk-free interest rate	1.23%
Dividend yield	0.00%
Weighted-average fair value of warrants (in dollars per share)	$ 2.78
Short-term Warrants [Member]
Expected price volatility		102.00%	80.00%
Expected term (in years) (Year)		3 years 65 days	4 years 65 days
Risk-free interest rate		1.51%	1.58%
Dividend yield		0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)		$ 2.47	$ 1.16
Expected price volatility		102.00%	80.00%
Expected term (in years) (Year)		3 years 65 days	4 years 65 days
Risk-free interest rate		1.51%	1.58%
Dividend yield		0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)		$ 2.47	$ 1.16
Long-term Warrants [Member]
Expected price volatility		102.00%	80.00%
Expected term (in years) (Year)		3 years 65 days	4 years 65 days
Risk-free interest rate		1.51%	1.58%
Dividend yield		0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)		$ 2.55	$ 1.16
Expected price volatility		102.00%	80.00%
Expected term (in years) (Year)		3 years 65 days	4 years 65 days
Risk-free interest rate		1.51%	1.58%
Dividend yield		0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)		$ 2.55	$ 1.16
October 2015 Warrants [Member]
Expected price volatility	75.50%	96.00%	77.50%
Expected term (in years) (Year)	5 years	3 years 302 days	4 years 302 days
Risk-free interest rate	1.38%	1.66%	1.72%
Dividend yield	0.00%	0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)	$ 2.82	$ 2.60	$ 1.21
Expected price volatility	75.50%	96.00%	77.50%
Expected term (in years) (Year)	5 years	3 years 302 days	4 years 302 days
Risk-free interest rate	1.38%	1.66%	1.72%
Dividend yield	0.00%	0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)	$ 2.82	$ 2.60	$ 1.21

Note 10 - Warrant Liability - O

Note 10 - Warrant Liability - Outstanding Warrant Liability (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Oct. 27, 2015	Dec. 31, 2014	Dec. 31, 2013
July 2011 Warrants, Shares (in shares)	565	1,458		197	192
July 2011 Warrants, Warrant Liability	$ 1,446,000	$ 1,450,000
The 2011 Warrants [Member]
July 2011 Warrants, Shares (in shares)	49
July 2011 Warrants, Warrant Liability	$ 126,000		$ 360,821
Long-term Warrants [Member]
July 2011 Warrants, Shares (in shares)	105
July 2011 Warrants, Warrant Liability	$ 267,000
Short-term Warrants [Member]
July 2011 Warrants, Shares (in shares)	127
July 2011 Warrants, Warrant Liability	$ 312,000
October 2015 Warrants [Member]
July 2011 Warrants, Shares (in shares)	284
July 2011 Warrants, Warrant Liability	$ 741,000
July 2011, Long-term, Short-term, and October 2015 Warrants [Member]
July 2011 Warrants, Shares (in shares)	565
July 2011 Warrants, Warrant Liability	$ 1,446,000

Note 11 - Stockholders' Equit56

Note 11 - Stockholders' Equity (Deficit) (Details Textual)	Aug. 01, 2016USD ($)shares	May 05, 2016USD ($)shares	Apr. 04, 2016USD ($)$ / sharesshares	Feb. 16, 2016USD ($)$ / sharesshares	Dec. 11, 2015	Oct. 27, 2015USD ($)$ / sharesshares	Oct. 22, 2015	May 22, 2015USD ($)$ / sharesshares	Mar. 06, 2015USD ($)$ / sharesshares	Oct. 16, 2014USD ($)shares	Mar. 25, 2014USD ($)$ / sharesshares	Oct. 31, 2015$ / sharesshares	May 31, 2015$ / sharesshares	Jul. 31, 2011$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Sep. 30, 2016USD ($)shares	Sep. 30, 2016USD ($)shares	Sep. 29, 2016$ / shares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Sep. 28, 2016$ / shares	May 31, 2016shares	Feb. 29, 2016$ / shares	Mar. 03, 2015$ / shares	Dec. 31, 2013$ / shares
Preferred Stock, Shares Authorized															5,000,000				5,000,000	5,000,000
Units Issued During Period											224,000
Common Stock Shares Per Unit											1
Warrants per Unit											1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right											6.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											56,000				363,523	3,613,284	3,613,284		363,523				2,039,530
Sale of Stock, Price Per Share | $ / shares						$ 5					$ 30
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares											$ 39			$ 33.25	$ 1,810			$ 3.15	$ 1,810	$ 5,190	$ 35,230	$ 19.50				$ 43,000
Warrant Date of Issuance of Term											1 year 180 days
Proceeds from Issuance of Common Stock | $						$ 1,900,000			$ 4,700,000		$ 6,700,000								$ 13,648,000	$ 11,519,000	$ 227,000
Expense Related to Distribution or Servicing and Underwriting Fees | $						$ 400,000			$ 200,000		470,000
Noninterest Expense Offering Cost | $											211,000
Stock Issued During Period, Shares, New Issues				1,518,567		492,000		435,746
Investment Warrants, Exercise Price | $ / shares						$ 5						$ 5
Class of Warrant or Right Issued During Period																			3,087	1,317	55
Private Placement, Commission Percentage			6.00%	6.00%				6.00%
Warrant Expiration Term						5 years						5 years
Stock Issued During Period, Value, New Issues | $				$ 2,800,000
Common Stock, Par or Stated Value Per Share | $ / shares															$ 0.01				$ 0.01	$ 0.01
Proceeds from Warrant Exercises | $															$ 900,000	$ 6,600,000
Class of Warrants or Rights, Exercises in Period															363,523	3,613,284			3,977
Warrants Exercised, Commission Percentage															6.00%	6.00%	6.00%		6.00%
Warrants Exercised, Commission Paid | $															$ 32,000	$ 338,000	$ 338,000		$ 32,000
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Warrants Issued														139,520
Class of Warrant or Right, Exercise Price, Discount from Market Price																		16.00%
Fair Value Adjustment of Warrants | $																			$ 270,000
Preferred Stock, Shares Outstanding															0				0	0
General and Administrative Expense [Member]
Fair Value Adjustment of Warrants | $																	$ 270,000
Maximum [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						468,280						442,800
Long-term Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																									$ 16.25
Short-term Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																									$ 15
July 2011, March 2015, and October 2015 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights															363,523	3,613,284	3,613,284		363,523
Proceeds from Warrant Exercises | $															$ 900,000	$ 6,900,000
Private Placement [Member]
Units Issued During Period									370,993
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,047,121	2,039,530	3,086,651						370,933
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 1.91
Warrant Date of Issuance of Term													12 years
Proceeds from Issuance of Common Stock | $								$ 7,300,000
Expense Related to Distribution or Servicing and Underwriting Fees | $								$ 900,000
Stock Issued During Period, Shares, New Issues	2,094,241	4,079,058	6,173,299
Unit Purchase Agreement Shares Per Unit | $ / shares								$ 15.75
Investment Warrants, Exercise Price | $ / shares								$ 19.50					$ 19.50
Class of Warrant or Right Issued During Period								217,873					217,873
Warrant Expiration Term			4 years
Common Stock, Par or Stated Value Per Share | $ / shares			$ 0.01
Sale of Stock, Consideration Received on Transaction | $	$ 4,000,000	$ 7,800,000	$ 11,800,000
Number of Sequential Trading Days			5 days
Number of Tranches for Private Placement			2
Private Placement [Member] | Minimum [Member]
Common Stock, Closing Price | $ / shares			$ 4
Private Placement [Member] | Outside Investors [Member]
Unit Purchase Agreement Shares Per Unit | $ / shares									$ 12.50
Private Placement [Member] | Company Insiders [Member]
Unit Purchase Agreement Shares Per Unit | $ / shares									$ 15
Private Placement [Member] | Long-term Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									278,200
Warrant Date of Issuance of Term									5 years
Investment Warrants, Exercise Price | $ / shares									$ 16.25
Warrant Expiration Term							5 years
Private Placement [Member] | Short-term Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									370,933
Warrant Date of Issuance of Term									1 year 90 days
Investment Warrants, Exercise Price | $ / shares									$ 15
Warrant Expiration Term							1 year 90 days
Mr. Fu [Member]
Stock Issued During Period, Shares, New Issues				696,590
Shares Issued, Price Per Share | $ / shares				$ 1.81
Mr. Fu [Member] | July 2011, March 2015, and October 2015 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																								$ 1.81
Shares Issued, Price Per Share | $ / shares																								$ 1.81
Pioneer Pharma Co. [Member]
Stock Issued During Period, Shares, New Issues				696,590
Shares Issued, Price Per Share | $ / shares				$ 1.91
Mr. Sieczkarek [Member]
Stock Issued During Period, Shares, New Issues				125,387
Shares Issued, Price Per Share | $ / shares				$ 1.91
Ascendiant Capital Markets [Member]
Proceeds from Issuance of Common Stock | $																					1,200,000
Maximum Common Stock Aggregate Proceeds Pursuant to Offering Agreement | $										$ 10,000,000
Percent of Gross Proceeds on Common Stock Sold, Commissions										3.00%
Stock Issued During Period, Shares, New Issues										1,300,000
Sales Commissions and Fees | $																					81,000
China Kington Asset Management Co. Ltd. [Member] | Private Placement [Member]
Payments of Stock Issuance Costs | $			$ 618,000	$ 155,000				$ 408,000
Net of Offering Costs and Commissions [Member]
Proceeds from Issuance of Common Stock | $						$ 2,300,000			$ 4,500,000		$ 6,000,000
Net of Offering Costs and Commissions [Member] | Private Placement [Member]
Proceeds from Issuance of Common Stock | $								$ 6,400,000
Net of Offering Costs and Commissions [Member] | Ascendiant Capital Markets [Member]
Proceeds from Issuance of Common Stock | $																					$ 1,100,000
In Exchange for Waiver [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues								635,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio					25														25

Note 11 - Stockholders' Equit57

Note 11 - Stockholders' Equity (Deficit) - Outstanding Warrants (Details) - $ / shares	3 Months Ended		12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Outstanding, Warrants (in shares)			1,458	197	192
Outstanding, Weighted average exercise price (in dollars per share)			$ 5,190	$ 35,230	$ 43,000
Warrants granted, Warrants (in shares)			3,087	1,317	55
Warrants granted, Weighted average exercise price (in dollars per share)			$ 1,910	$ 7,400	$ 39,000
Warrants expired, Warrants (in shares)			(3)	(56)	(50)
Warrants expired, Weighted average exercise price (in dollars per share)			$ 78,130	$ 39,000	$ 68,750
Outstanding, Warrants (in shares)	565		565	1,458	197
Outstanding, Weighted average exercise price (in dollars per share)	$ 1,810		$ 1,810	$ 5,190	$ 35,230
Warrants exercised, Warrants (in shares)	(363,523)	(3,613,284)	(3,977)
Warrants exercised, Weighted average exercise price (in dollars per share)			$ 1,950

Note 12 - Equity-based Compen58

Note 12 - Equity-based Compensation (Details Textual) - USD ($)	May 26, 2016	May 30, 2015	Jan. 31, 2016	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2012	Jan. 31, 2011	Jan. 31, 2010	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Oct. 31, 2012	Dec. 31, 2012	Oct. 31, 2007
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period														2 years 7 days
Proceeds from Stock Options Exercised																$ 4,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value														0		$ 4,000	$ 32,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized														$ 1,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross														1,227,000		85,000	68,000
Allocated Share-based Compensation Expense														$ 1,751,000		$ 1,382,000	$ 1,042,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period														0			2,000
Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross														1,139,000	59,000		52,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period														64,000		16,000	2,000
Allocated Share-based Compensation Expense														$ 1,489,000		$ 1,193,000	$ 853,000
Mr. Cashion and Mr. Wicks [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period											4 years	90 days
Allocated Share-based Compensation Expense											$ 185,000
Mr. Cashion and Mr. Wicks [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period									90 days	4 years
Mr. Radaelli and Mr. McPherson [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost													$ 58,000
Exercised [Member]
Proceeds from Stock Options Exercised														$ 0		0	34,000
The 2007 Omnibus Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance																				40,000
Annual Increase, Number of Shares, Percentage																			4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	1,124,826	82,461		32,646	59,157	40,000	37,427	37,207
Increase (Decrease) in Number of Shares Available for Grant			139,449
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	2,318,486
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant														53,587
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent														100.00%
Share-based Compensation Arrangement by Share-based Payment Award Threshold Purchase Price of Common Stock Percent														10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period														10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period														4 years
The 2007 Omnibus Incentive Plan [Member] | Shareholder of More Than 10% [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent														110.00%
The 2007 Omnibus Incentive Plan [Member] | Maximum [Member]
Increase (Decrease) in Number of Shares Available for Grant																		40,000
Percentage of Number of Common Shares Outstanding																		4.00%
Nonemployees [Member]
Allocated Share-based Compensation Expense														$ 262,000		$ 188,000	$ 189,000
Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued														89,000		27,000	14,000
Stock Issued During Period, Shares, Issued for Services														41,000		500	600

Note 12 - Equity-based Compen59

Note 12 - Equity-based Compensation - Stock Options Outstanding (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Options outstanding (in shares)	388,000	323,000	287,000
Weighted-average exercise price, outstanding (in dollars per share)	$ 32.03	$ 38.25	$ 42
Weighted-average remaining contractual life, outstanding (Year)	8 years 255 days	6 years 73 days	6 years 109 days	6 years 219 days
Aggregate intrinsic value, outstanding	$ 702	$ 19	$ 23	$ 422
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,227,000	85,000	68,000
Weighted-average exercise price, options granted (in dollars per share)	$ 2.74	$ 11.20	$ 22.50
Options exercised (in shares)	0		(2,000)
Weighted-average exercise price, options exercised (in dollars per share)			$ 14
Options forfeited/cancelled (in shares)	(116,000)	(28,000)	(29,000)
Weighted-average exercise price, options forfeited/cancelled (in dollars per share)	$ 28.27	$ 30.58	$ 36.50
Options outstanding (in shares)	1,489,000	388,000	323,000	287,000
Weighted-average exercise price, outstanding (in dollars per share)	$ 8.38	$ 32.03	$ 38.25	$ 42
Options granted (in shares)	1,227,000	85,000	68,000
Weighted-average exercise price, options granted (in dollars per share)	$ 2.74	$ 11.20	$ 22.50
Weighted-average remaining contractual life, outstanding (Year)	8 years 255 days	6 years 73 days	6 years 109 days	6 years 219 days
Options, vested and expected to vest (in shares)	1,466,000
Weighted-average exercise price, vested and expected to vest (in dollars per share)	$ 8.45
Weighted-average remaining contractual life, vested and expected to vest (Year)	8 years 219 days
Aggregate intrinsic value, vested and expected to vest	$ 691
Options, vested (in shares)	402,000
Weighted-average exercise price, vested (in dollars per share)	$ 22.45
Weighted-average remaining contractual life, vested (Year)	6 years 219 days
Options, exercisable (in shares)	402,000
Weighted-average exercise price, exercisable (in dollars per share)	$ 22.45
Weighted-average remaining contractual life, exercisable (Year)	6 years 219 days
Restricted Stock Units (RSUs) [Member]
Restricted stock units granted (in shares)	104,000	16,000	3,000
Restricted stock units vested (in shares)	(114,000)	(6,000)	(4,000)
Restricted stock units granted (in shares)	104,000	16,000	3,000
Restricted stock units vested (in shares)	(114,000)	(6,000)	(4,000)
Restricted stock units cancelled (in shares)		(2,000)

Note 12 - Equity-based Compen60

Note 12 - Equity-based Compensation - The Weighted-average Assumptions Used in Determining the Value of Options Granted (Details) - Employee [Member] - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Expected price volatility	84.47%	77.22%	76.88%
Expected term (in years) (Year)	7 years 10 days	6 years 292 days	6 years 182 days
Risk-free interest rate	1.57%	1.76%	2.06%
Dividend yield	0.00%	0.00%	0.00%
Weighted-average fair value of options granted during the period (in dollars per share)	$ 2.06	$ 7.35	$ 15.25

Note 12 - Equity-based Compen61

Note 12 - Equity-based Compensation - The Weighted-average Assumptions Used in Determining the Value of Options Granted Non-employee (Details) - Nonemployees [Member] - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Expected price volatility	87.68%	83.77%	79.10%
Expected term (in years) (Year)	10 years	9 years 219 days	8 years 219 days
Risk-free interest rate	1.61%	2.18%	2.28%
Dividend yield	0.00%	0.00%	0.00%
Weighted-average fair value of options granted during the period (in dollars per share)	$ 2.29	$ 7.15	$ 15.25

Note 12 - Equity-based Compen62

Note 12 - Equity-based Compensation - Summary of the Stock-based Compensation Expense Included in Results of Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Allocated Share-based Compensation Expense	$ 1,751	$ 1,382	$ 1,042
Research and Development Expense [Member]
Allocated Share-based Compensation Expense	195	449	376
Selling and Marketing Expense [Member]
Allocated Share-based Compensation Expense	132
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense	$ 1,424	$ 933	$ 666

Note 13 - License, Collaborat63

Note 13 - License, Collaboration and Distribution Agreements (Details Textual) - USD ($)	Jun. 01, 2013	Feb. 07, 2012	Jan. 31, 2013	Oct. 31, 2012	Sep. 30, 2012	Jan. 31, 2012	Oct. 31, 2012	Sep. 30, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Mar. 25, 2014
Fees and Commissions, Other						$ 312,500
Contracts Revenue			$ 312,500								$ 625,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right												6.25
Tranche One [Member]
Purchase Agreement Units					800,000
Purchase Agreement Unit Price Per Share					$ 1.25
Tranche Two [Member]
Purchase Agreement Units				1,200,000
Purchase Agreement Unit Price Per Share				$ 1.25
Purchase Unit Agreement Total Units Fair Value				$ 3,500,000
Reallocated from Deferred Revenue [Member]
Stockholders' Equity, Period Increase (Decrease)							$ 600,000
Restricted Stock Purchase [Member]
Contracts Revenue							2,500,000
Excess Fair Value Over Proceeds Received From Purchase							$ 1,000,000
Maximum [Member]
Sales Discounts, Goods								$ 500,000
Pioneer Pharma Co. [Member] | Restricted Stock [Member]
Unit Purchase Agreement Shares Per Unit							$ 1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				1			1
Virbac [Member]
Deferred Revenue									$ 246,000
Neutrophase [Member]
Deferred Revenue									1,000,000	$ 1,100,000	1,200,000
Integrated Healing Technologies, LLC [Member]
Deferred Revenue									653,000	674,000	679,000
Commission Payment Received Upfront		$ 750,000
Principal Business Enterprise, Inc. [Member]
Deferred Revenue									194,000	195,000	196,000
Commission Payment Received Upfront	$ 200,000
Avenova Distribution Agreements [Member]
Deferred Revenue									1,924,000	24,000
Contracts Revenue									$ 7,300,000	$ 947,000	$ 4,000

Note 13 - License, Collaborat64

Note 13 - License, Collaboration and Distribution Agreements - Deferred Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Product sales	$ 11,617	$ 4,146	$ 684
Total revenue recognized	11,897	4,381	1,054
Pioneer Pharma Co. [Member] | Neutrophase [Member]
Amortization of upfront technology access fee	94	25	47
Product sales	324	70	161
Total revenue recognized	418	95	208
Integrated Healing Technologies, LLC [Member] | Neutrophase [Member]
Amortization of upfront technology access fee	21	5	7
Product sales	332	34	101
Total revenue recognized	353	39	108
Principal Business Enterprise, Inc. [Member] | Neutrophase [Member]
Amortization of upfront technology access fee		1	4
Product sales	22	66	104
Total revenue recognized	22	67	108
Materials Equipment And Contract Study Costs [Member] | Virbac [Member]
Other Income			$ 39

Note 14 - Employee Benefit Pl65

Note 14 - Employee Benefit Plan (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
The 401(k) Plan [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0

Note 15 - Income Taxes (Details

Note 15 - Income Taxes (Details Textual) $ in Millions	Dec. 31, 2016USD ($)
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Tax Benefits Compensation and Benefits, Share-based Compensation Cost	$ 1.1
State and Local Jurisdiction [Member] | California Franchise Tax Board [Member]
Tax Benefits Compensation and Benefits, Share-based Compensation Cost	$ 0.7

Note 15 - Income Taxes - Federa

Note 15 - Income Taxes - Federal and State Income Tax Provisions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current
State	$ 2	$ 2	$ 2
Total current tax expense	2	2	2
Deferred
Income tax provision	$ 2	$ 2	$ 2

Note 15 - Income Taxes - Summar

Note 15 - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating losses	$ 34,902	$ 31,464
Accruals	287	403
Deferred revenue	829	954
Stock options	1,894	1,558
Other deferred tax assets	765	652
Total deferred tax assets	38,677	35,031
Deferred tax liabilities:
Property and equipment	(32)	(28)
Total deferred tax liabilities	(32)	(28)
Valuation allowance	(38,645)	(35,003)
Net deferred taxes

Note 15 - Income Taxes - Valuat

Note 15 - Income Taxes - Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Valuation allowance	$ 3,642	$ 8,101	$ 6,286

Note 15 - Income Taxes - Summ70

Note 15 - Income Taxes - Summary of Tax Credit Carryforwards (Details) $ in Thousands	Dec. 31, 2016USD ($)
State and Local Jurisdiction [Member]
Tax Credits	$ 282
Expiration Years 2024 - 2036 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Net Operating Losses	90,165
Expiration Years 2028 - 2036 [Member] | State and Local Jurisdiction [Member]
Net Operating Losses	78,219
Expiration Years 2031 - 2036 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Tax Credits	$ 1,316

Note 15 - Income Taxes - Effect

Note 15 - Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income tax provision (benefit) at federal statutory rate	$ (4,471)	$ (6,439)	$ (5,154)
State tax	(157)	(1,060)	(818)
ISO-related expense for GAAP	52	164	144
Change in valuation allowance	3,641	8,101	6,286
Revaluation of warrant liability	806	(731)	(565)
Tax credits	(31)	(123)	(44)
Other	162	90	153
Total	$ 2	$ 2	$ 2

Note 15 - Income Taxes - Unreco

Note 15 - Income Taxes - Unrecognized Tax Benefit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Unrecognized benefit - beginning of period	$ 957	$ 811
Gross increases - current period tax positions	17	76
Unrecognized benefit - end of period	$ 974	$ 957

Note 16 - Related Party Trans73

Note 16 - Related Party Transactions (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accounts Receivable, Related Parties	$ 75,000	$ 0
China Kingston [Member] | Related-party Commission Fees [Member]
Related Party Transaction, Expenses from Transactions with Related Party	1,100,000	408,000	$ 0
Amortization Revenue [Member] | Neutrophase [Member]
Other Income	$ 418,000	$ 95,000	$ 208,000